Literature DB >> 24889540

Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs.

Mi-Ok Kim1, Chunyan Liu, Feifang Hu, J Jack Lee.   

Abstract

Delay in the outcome variable is challenging for outcome-adaptive randomization, as it creates a lag between the number of subjects accrued and the information known at the time of the analysis. Motivated by a real-life pediatric ulcerative colitis trial, we consider a case where a short-term predictor is available for the delayed outcome. When a short-term predictor is not considered, studies have shown that the asymptotic properties of many outcome-adaptive randomization designs are little affected unless the lag is unreasonably large relative to the accrual process. These theoretical results assumed independent identical delays, however, whereas delays in the presence of a short-term predictor may only be conditionally homogeneous. We consider delayed outcomes as missing and propose mitigating the delay effect by imputing them. We apply this approach to the doubly adaptive biased coin design (DBCD) for motivating pediatric ulcerative colitis trial. We provide theoretical results that if the delays, although non-homogeneous, are reasonably short relative to the accrual process similarly as in the iid delay case, the lag is also asymptotically ignorable in the sense that a standard DBCD that utilizes only observed outcomes attains target allocation ratios in the limit. Empirical studies, however, indicate that imputation-based DBCDs performed more reliably in finite samples with smaller root mean square errors. The empirical studies assumed a common clinical setting where a delayed outcome is positively correlated with a short-term predictor similarly between treatment arm groups. We varied the strength of the correlation and considered fast and slow accrual settings.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  delayed outcome; doubly adaptive biased coin design; imputation; outcome adaptive randomization

Mesh:

Year:  2014        PMID: 24889540      PMCID: PMC4159410          DOI: 10.1002/sim.6222

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Empirical likelihood analysis of the Buckley-James estimator.

Authors:  Mai Zhou; Gang Li
Journal:  J Multivar Anal       Date:  2008-04       Impact factor: 1.473

2.  Adaptive survival trials.

Authors:  W F Rosenberger; P Seshaiyer
Journal:  J Biopharm Stat       Date:  1997-11       Impact factor: 1.051

Review 3.  Corticosteroids and growth.

Authors:  J S Hyams; D E Carey
Journal:  J Pediatr       Date:  1988-08       Impact factor: 4.406

4.  The natural history of corticosteroid therapy for ulcerative colitis in children.

Authors:  Jeffrey Hyams; James Markowitz; Trudy Lerer; Anne Griffiths; David Mack; Athos Bousvaros; Anthony Otley; Jonathan Evans; Mariann Pfefferkorn; Joel Rosh; Robert Rothbaum; Subra Kugathasan; Adam Mezoff; Robert Wyllie; Vasundhara Tolia; J Fernando delRosario; M Susan Moyer; Maria Oliva-Hemker; Neal Leleiko
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-03       Impact factor: 11.382

5.  Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study.

Authors:  Jeffrey S Hyams; Trudy Lerer; David Mack; Athos Bousvaros; Anne Griffiths; Joel Rosh; Anthony Otley; Jonathan Evans; Michael Stephens; Marsha Kay; David Keljo; Marian Pfefferkorn; Shehzad Saeed; Wallace Crandall; Sonia Michail; Michael D Kappelman; Andrew Grossman; Charles Samson; Boris Sudel; Maria Oliva-Hemker; Neal Leleiko; James Markowitz
Journal:  Am J Gastroenterol       Date:  2011-01-11       Impact factor: 10.864

6.  Clinical outcome of ulcerative colitis in children.

Authors:  J S Hyams; P Davis; K Grancher; T Lerer; C J Justinich; J Markowitz
Journal:  J Pediatr       Date:  1996-07       Impact factor: 4.406

7.  Continuous Bayesian adaptive randomization based on event times with covariates.

Authors:  Ying Kuen Cheung; Lurdes Y T Inoue; J Kyle Wathen; Peter F Thall
Journal:  Stat Med       Date:  2006-01-15       Impact factor: 2.373

Review 8.  Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

Authors:  Joel R Rosh; Thomas Gross; Petar Mamula; Anne Griffiths; Jeffrey Hyams
Journal:  Inflamm Bowel Dis       Date:  2007-08       Impact factor: 5.325

9.  Using short-term response information to facilitate adaptive randomization for survival clinical trials.

Authors:  Xuelin Huang; Jing Ning; Yisheng Li; Elihu Estey; Jean-Pierre Issa; Donald A Berry
Journal:  Stat Med       Date:  2009-05-30       Impact factor: 2.373

10.  Outcome following infliximab therapy in children with ulcerative colitis.

Authors:  Jeffrey S Hyams; Trudy Lerer; Anne Griffiths; Marian Pfefferkorn; Michael Stephens; Jonathan Evans; Anthony Otley; Ryan Carvalho; David Mack; Athos Bousvaros; Joel Rosh; Andrew Grossman; Gitit Tomer; Marsha Kay; Wallace Crandall; Maria Oliva-Hemker; David Keljo; Neal LeLeiko; James Markowitz
Journal:  Am J Gastroenterol       Date:  2010-01-26       Impact factor: 10.864

View more
  4 in total

1.  Improving clinical trials using Bayesian adaptive designs: a breast cancer example.

Authors:  Wei Hong; Sue-Anne McLachlan; Melissa Moore; Robert K Mahar
Journal:  BMC Med Res Methodol       Date:  2022-05-04       Impact factor: 4.612

2.  A novel evaluation of optimality for randomized controlled trials.

Authors:  Jo Wick; Scott M Berry; Hung-Wen Yeh; Won Choi; Christina M Pacheco; Christine Daley; Byron J Gajewski
Journal:  J Biopharm Stat       Date:  2016-06-13       Impact factor: 1.051

3.  Some performance considerations when using multi-armed bandit algorithms in the presence of missing data.

Authors:  Xijin Chen; Kim May Lee; Sofia S Villar; David S Robertson
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752

4.  Bayesian selective response-adaptive design using the historical control.

Authors:  Mi-Ok Kim; Nusrat Harun; Chunyan Liu; Jane C Khoury; Joseph P Broderick
Journal:  Stat Med       Date:  2018-06-13       Impact factor: 2.373

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.